Condition
IDH1 Mutation clinical trials and research
As of November 12, 2026, Find a Trial lists 5 IDH1 Mutation clinical trials that are recruiting, at sites in 8 countries (most in United States (4), China (1), Australia (1)). By phase: Phase 2 (4), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 8Countries
Newest IDH1 Mutation clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Olutasidenib after venetoclax in IDH1-mutated relapsed/refractory AML | Phase 2 | Winston-Salem, North Carolina | Recruiting | Mar 13, 2026 |
| Combination treatment for newly diagnosed acute myeloid leukemia with IDH1 mutation | Phase 2 | Miami, Florida | Recruiting | Jan 20, 2025 |
| Ivosidenib maintenance after allogeneic stem cell transplant for IDH1-mutant AML | Phase 2 | Atlanta, Georgia and 6 other locations | Recruiting | Nov 27, 2024 |
| Venetoclax with ivosidenib and azacitidine for newly diagnosed AML with an IDH1 mutation | Phase 1/2 | Tianjin, Tianjin Municipality | Recruiting | Sep 25, 2024 |
| Treatment of high-grade glioma in young patients using olutasidenib and temozolomide | Phase 2 | Aurora, Colorado and 19 other locations | Recruiting | Dec 8, 2023 |
All recruiting trials (5)
-
Olutasidenib after venetoclax in IDH1-mutated relapsed/refractory AML
This study tests whether olutasidenib can help adults with IDH1-mutated AML that has relapsed or not responded to venetoclax-based therapy.
-
Combination treatment for newly diagnosed acute myeloid leukemia with IDH1 mutation
This study is testing a new combination treatment for people with newly diagnosed acute myeloid leukemia and an IDH1 mutation to see if it works better and has fewer side effects than standard chemotherapy.
-
Ivosidenib maintenance after allogeneic stem cell transplant for IDH1-mutant AML
This trial tests whether taking ivosidenib versus a placebo after allogeneic stem cell transplant can prevent relapse in adults with IDH1-mutant AML.
-
Venetoclax with ivosidenib and azacitidine for newly diagnosed AML with an IDH1 mutation
This treatment tests whether combining venetoclax, ivosidenib, and azacitidine helps people newly diagnosed with AML that has an IDH1 mutation.
-
Treatment of high-grade glioma in young patients using olutasidenib and temozolomide
This study is testing if a new combination of olutasidenib and temozolomide can help young patients with high-grade gliomas that have a specific mutation feel better after their radiotherapy.
Related topics
Quick answers
How many IDH1 Mutation clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 8 countries. The most sites are in United States (4 trials), China (1 trial), Australia (1 trial), Canada (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 4, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.